Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

This was the stock's third consecutive day of losses.

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

"One of the approaches I used in my project was bridging western medicine and also traditional indigenous practices." ...

Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to the need for the Supreme Court to weigh in.

The top two students from the senior division will represent Berks County at the Regeneron International Science and Engineering Fair this May in Columbus, Ohio. The winners, school and project name ...

Cummings won the prize for her research on Native American myopathy, also known as the muscle disorder stac3. WTVD spoke with ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

General Manager at Sanofi UK and Ireland, Rippon Ubhi, and Jim Shannon MP discuss the burden of chronic obstructive pulmonary ...